Veritas Genetics, an international leader in genomic medicine and precision diagnostics, announces the appointment of Dr. Lluís Armengol, PhD., as Chief Scientific Officer and Dr. Claudio Catalli, MD, to the role of Medical Geneticist and Clinical European Director. 

Lluís Armengol, PhD, is a geneticist and genomic scientist with more than two decades of experience in human genetics, structural genomic variation, and the development of advanced diagnostic technologies. He holds a BSc in Biochemistry and a PhD in Biology from the University of Barcelona, and developed his scientific career in internationally recognized institutions such as the Institut de Recerca Oncològica (IRO), the Eleanor Roosevelt Institute (University of Colorado), and the Centre for Genomic Regulation (CRG) in Barcelona.

He was co-founder and, since 2009, Scientific Director and CEO of qGenomics, where he led the design, validation and clinical implementation of genomic technologies—including chromosomal microarrays, next-generation sequencing, and structural variation analysis—applied to prenatal and postnatal diagnosis, neurodevelopmental disorders, rare diseases, carrier screening and oncology. His work spans both academic and translational research, with significant contributions to the study of copy number variation, segmental duplications, structural variants, and the genomic mechanisms underlying neurodevelopmental and rare diseases. Dr. Armengol has served as principal investigator or co-investigator in numerous competitive national and European research projects, and is author or co-author of more than 60 peer-reviewed publications in high-impact journals such as Nature, New England Journal of Medicine, Nature Genetics, and Genome Biology. 

His recent appointment as Chief Scientific Officer at Veritas Genetics strengthens the integration of state-of-the-art scientific evidence into the company’s diagnostic portfolio and supports the development of collaborative studies with hospitals and leading research groups.

 “My goal is to reinforce Veritas’ scientific leadership and its role as a trusted partner for hospitals and research institutions. Genomics must serve as a bridge between scientific evidence and clinical decision-making,” states Dr. Lluís Armengol, PhD.

Dr. Claudio Catalli, MD, specialist in Clinical Genetics, brings over fifteen years of international experience combining clinical practice, research, and advisory work in human genetics. Graduated cum laude in Medicine and specialized in Clinical Genetics at the University of Tor Vergata (Rome), he has developed a distinguished career across leading European institutions.

He served as Clinical Geneticist at the Hospital Virgen del Camino (Pamplona, Spain), later becoming Head of the Genetics Unit at the Hospital Virgen de la Salud (Toledo, Spain). Since 2017, he has been part of the Hospital Universitario Cruces (Osakidetza, Spain), where he contributes to clinical assessment and research in adult-onset neurogenetic and rare diseases, overseeing postnatal cytogenetic and NGS interpretation workflows.

As Medical Geneticist and Clinical European Director, Dr. Catalli will coordinate Veritas’ clinical network and strengthen partnerships with hospitals and healthcare professionals across Europe, advancing genomics-based approaches to risk stratification, prevention, and precision medicine.

“Genomics is not only an individual diagnostic resource; it is a strategic foundation for building more efficient, equitable, and preventive healthcare systems. Veritas has the clinical infrastructure and scientific expertise needed to lead this evolution,” says Dr. Claudio Catalli.

According to Dr. Luis Izquierdo, MD, Chief Medical Officer of Veritas Genetics:

“The appointments of Dr. Catalli and Dr. Armengol reinforce the core scientific and clinical foundation of Veritas Genetics. Their complementary expertise— spanning transactional genomics, advanced diagnostics, clinical variant interpretation, and the integration of genomics into healthcare workflows— will be fundamental in advancing our strategy to deliver predictive and personalized medicine with demonstrable clinical benefits. Their leadership enhances Veritas’ ability to serve as a trusted strategic partner to hospitals, health agencies, public health systems, and scientific organizations worldwide,”.

These appointments significantly strengthen Veritas Genetics’ multidisciplinary team and strategic leadership, accelerating the implementation of genomic medicine. Enhanced expertise will drive the development of new evidence-based healthcare models and expand our capacity for scientific collaboration and clinical research. Ultimately, this directly reinforces our role as a trusted partner to hospitals, insurers, and public health systems, supporting critical services such as genomic screening, risk stratification, pharmacogenomics, and advanced diagnostics.

About Veritas Genetics

Veritas Genetics is a leading clinical genomics company offering advanced human-genome sequencing and interpretation services to enable accurate diagnosis, personalized prevention, and improved healthcare decision-making.

Its portfolio supports healthcare professionals across preventive genomics, genetic diagnostics, oncology, cardiology, pharmacogenomics, and reproductive medicine.

Veritas Genetics combines scientific excellence with cutting-edge technology to promote the integration of genomics into daily clinical practice and to advance a more predictive, preventive, and personalized model of healthcare.

Through a continued commitment to innovation and accessibility, the company works to transform how health and wellness are understood and managed worldwide.